Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6%

Tharimmune, Inc. (NASDAQ:THAR) saw a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 26,300 shares, a drop of 58.6% from the January 31st total of 63,500 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average daily volume of 95,800 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

THAR has been the topic of several analyst reports. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw began coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 target price on the stock.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is currently owned by institutional investors.

Tharimmune Trading Down 1.4 %

THAR opened at $1.43 on Friday. Tharimmune has a one year low of $1.36 and a one year high of $7.46. The business’s fifty day moving average is $1.97 and its two-hundred day moving average is $2.30.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).